Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Retinoblastoma 26Advanced Solid Tumors 18Mesothelioma 16Mesothelioma, Malignant 15Unspecified Adult Solid Tumor, Protocol Specific 13Solid Tumors 9Advanced Solid Tumor 6Solid Tumor 4Neuroblastoma 4Unspecified Childhood Solid Tumor, Protocol Specific 3Sarcoma 3Retinal Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Medulloblastoma 3Central Nervous System Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Testicular Neoplasms 2Solid Tumor, Adult 2Rhabdoid Tumor 2Relapsed Pediatric Solid Tumor 2Osteosarcoma 2Optic Nerve Glioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma 2Choroid Plexus Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Astrocytoma 2

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × Carboplatin × Other solid neoplasm × Clear all
NCT07268040 2026-01-12

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡